TrialEuropean journal of cancer (Oxford, England : 1990)2020

Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.

Richard D Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.